Artificial intelligence-driven risk estimation, early detection, diagnostic characterisation and prognosis in hepatitis b-related hepatocellular carcinoma
Artificial Intelligence in Gastroenterology · 08.11.2026 · 7 (3)
DOI: 10.35712/aig.124278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Intelligence in Gastroenterology, online erschienen am 08.11.2026. Verfasst von Pranjal Kashiv und 5 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Chronic hepatitis B virus (HBV) infection remains the leading global antecedent of hepatocellular carcinoma (HCC), yet the surveillance framework on which early detection depends is constrained at both of its load-bearing points: The modest sensitivity of biannual ultrasonography for early-stage tumours, and the bounded discrimination of risk scores that compress a nonlinear, time-evolving process into a small set of additively weighted covariates. Artificial intelligence (AI) has been advanced as a corrective, but the term is applied loosely and the supporting evidence is drawn from heterogeneous populations and from clinical tasks that are frequently conflated. This narrative review appraises AI across four separable tasks in the HBV-HCC pathway: Risk estimation in chronic hepatitis B, early detection during surveillance, diagnostic characterisation of established lesions, and prognosis after diagnosis. We state what is and is not counted as AI, describe the search strategy and selection principles, and categorise every cited study according to whether its evidence is HBV-specific, mixed-aetiology, hepatitis C virus-derived, drawn from general HCC populations, or confined to recurrence and prognosis. Where machine-learning models built on routine clinical variables have been compared with established scores within a single validation cohort, they have discriminated more accurately. Convolutional networks have improved ultrasonographic lesion detection, serological and cell-free DNA methylation models have been applied to early-stage detection beyond alpha-fetoprotein, and multi-omics integration has been used for molecular subclassification. These findings rest on a literature that is predominantly retrospective and single-centre, in which external validation is the exception, calibration is reported inconsistently, explainability is uneven, and meta-analysts repeatedly judge the underlying studies to be at high risk of bias. Evidence drawn specifically from hepatitis B cohorts remains a minority of the published work, and no study has demonstrated that an AI-guided strategy improves stage at diagnosis or survival. Prospective multicentre validation, transparent calibration, adherence to TRIPOD+AI and PROBAST+AI, and deliberate inclusion of African and South Asian populations are therefore prerequisites rather than refinements.
Zitieren
APA
Kashiv, P., Balwani, M. R., Saxena, K., Tolani, P., Pasari, A., & Kute, V. B. (2026). Artificial intelligence-driven risk estimation, early detection, diagnostic characterisation and prognosis in hepatitis b-related hepatocellular carcinoma. Artificial Intelligence in Gastroenterology, 7(3). https://doi.org/10.35712/aig.124278
Vancouver
Kashiv P, Balwani MR, Saxena K, Tolani P, Pasari A, Kute VB. Artificial intelligence-driven risk estimation, early detection, diagnostic characterisation and prognosis in hepatitis b-related hepatocellular carcinoma. Artificial Intelligence in Gastroenterology. 2026;7(3). doi:10.35712/aig.124278
BibTeX
@article{Kashiv2026,
author = {Kashiv, Pranjal and Balwani, Manish Ramesh and Saxena, Khushboo and Tolani, Priyanka and Pasari, Amit and Kute, Vivek B},
title = {Artificial intelligence-driven risk estimation, early detection, diagnostic characterisation and prognosis in hepatitis b-related hepatocellular carcinoma},
journal = {Artificial Intelligence in Gastroenterology},
year = {2026},
volume = {7},
number = {3},
doi = {10.35712/aig.124278}
}
EUVIMED